NCT03455218View on ClinicalTrials.gov

Nitric Oxide Administration During Pediatric Cardiopulmonary Bypass Surgery to Prevent Platelet Activation

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

April 25, 2018

Primary Completion Date

April 20, 2019

Study Completion Date

May 5, 2019

Conditions
InflammationPlatelet Dysfunction
Interventions
DRUG

Nitric Oxide

20 ppm of Nitric Oxide gas delivered to the oxygenator for the duration of cardiopulmonary bypass

DRUG

Placebo

INOmax device connected to oxygenator, but no gas is delivered

DEVICE

INOmax

All patients will have the INOmax device connected to the oxygenator

Trial Locations (1)

53226

Children's Hospital of Wisconsin, Milwaukee

Sponsors

Collaborators (1)

Mallinckrodt
All Listed Sponsors
collaborator

Mallinckrodt

INDUSTRY

collaborator

Clinical & Translational Science Institute of Southeast Wisconsin

OTHER

collaborator

Versiti

OTHER

lead

Medical College of Wisconsin

OTHER